Chromosomal Crossover News and Research

RSS

ZEGERID OTC capsules offer more rapid acid reduction than Prevacid- 24HR delayed-release capsules

Merck Consumer Care today announced results of a head-to-head clinical study showing that ZEGERID OTC- offers greater and faster acid control than Prevacid- 24HR. While acid control is an industry standard measure for acid-reducing drugs, greater and faster acid control does not imply greater and faster heartburn symptom relief.

5 May 2010

Laughter increases production of antibodies and activates body's protective cells

Laughter is a highly complex process. Joyous or mirthful laughter is considered a positive stress (eustress) that involves complicated brain activities leading to a positive effect on health. Norman Cousins first suggested the idea that humor and the associated laughter can benefit a person's health in the 1970s. His ground-breaking work, as a layperson diagnosed with an autoimmune disease, documented his use of laughter in treating himself—with medical approval and oversight—into remission.

27 Apr 2010

Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting

Cumberland Pharmaceuticals Inc. today announced that results from a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, will be presented at the 2010 Digestive Disease Week meeting in New Orleans.

27 Apr 2010

Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that it has filed a request for an FDA meeting to advance the URG101 clinical program and mutually agreed with Oceana Therapeutics, Inc. to terminate their Consulting Agreement effective immediately.

24 Apr 2010

Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress

Boston-based medical technology firm Gelesis, Inc. unveiled its capsulated device Attiva™, and presented data showing that Attiva™ significantly increased the post-meal feeling of satiety and reduced hunger between meals in obese patients. This data was presented today at the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting & Clinical Congress.

23 Apr 2010

Exposure to dust after WTC collapse impairs ability to detect odors and sense irritants

Individuals involved in rescue, recovery, demolition, and clean-up after the World Trade Center (WTC) disaster on September 11, 2001, were exposed to a complex mixture of airborne smoke, dust, combustion gases, acid mists, and metal fumes. The impact of this exposure on responders' upper and lower respiratory function has been well documented, but little is known about its impact on their sensitivity to odor and irritants.

19 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

Trevena commences Phase I trial of TRV120027 biased ligand for acute decompensated heart failure

Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced the initiation of a Phase I clinical trial of TRV120027, a titratable i.v. agent designed for the treatment of acute decompensated heart failure. TRV120027 is a biased ligand that targets the angiotensin II type 1 receptor (AT1R) and induces a unique mode of signaling.

15 Apr 2010

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

XenoPort announced today that new data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the 62nd Annual American Academy of Neurology meeting in Toronto, Ontario.

12 Apr 2010

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

MAP Pharmaceuticals, Inc. today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX™ orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography.

8 Apr 2010

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma announced today initiation of the Company's first Phase 1 trial to evaluate the pharmacokinetic (PK) profiles of experimental controlled-release (CR) morphine and oxycodone formulations that will be incorporated into MoxDuo®CR. MoxDuo®CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain, an approximately US$7 billion dollar market worldwide.

31 Mar 2010

NIH grant for study on impact of gastric bypass surgery on Type II diabetes patients

Gastric bypass surgery, thought of by many as the last hope of morbidly obese people for losing weight, has many other benefits researchers are only beginning to understand.

25 Mar 2010

For undecided lawmakers, health care bill is personal

Politico: The decision on how to vote on the health care overhaul affects members differently than nearly any other issue. "[N]o other single issue — civil rights, Medicare, even war in this age of professional armies — quite matches the personal side of health care's stubborn details. … Everybody gets sick; everybody dies.

20 Mar 2010

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Hercules Technology Growth Capital, Inc., the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, today announced that it has committed over $52.0 million in structured debt financing to new and existing portfolio companies.

19 Mar 2010

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH).

19 Mar 2010

Hi-maize whole grain corn flour and Hi-maize resistant starch increase satiety

A University of Toronto (Toronto, Canada) research team, led by G. Harvey Anderson, Ph.D., just published results of a new study in the American Journal of Clinical Nutrition, showing that the quantity of resistant starch in foods correlates with blood glucose response and reduced food intake after two hours.

16 Mar 2010

Mental health experts cite positive aspects of March Madness, offer tips to temper drawbacks

The perfect storm of sporting events is nigh, and for three weeks people will become riveted by the David and Goliath matchups and Cinderella stories set against a backdrop of beers and big screens and bar food favorites.

16 Mar 2010

Step-up treatments may benefit children with asthma on low-dose inhaled corticosteroids

Children with asthma who continue to have symptoms while using low-dose inhaled corticosteroids could benefit from increasing the dosage or adding one of two asthma drugs, a new study by researchers at Washington University School of Medicine and other institutions finds.

3 Mar 2010

First Edition: March 2, 2010

Today's headlines highlight the latest on the White House's health reform strategy and a new lawsuit against California's largest for-profit health insurer.

2 Mar 2010

MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial

MAP Pharmaceuticals, Inc. today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

16 Feb 2010